The integration of SGLT2-is and CKM has the potential to revolutionize HF management in T1D by combining the cardiovascular benefits of SGLT2-is with a real-time strategy for DKA prevention. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.